Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 9/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL553905 | 0.92 | CTRB1 (0.61) | CTRB1CASP1SYKATM | |
| SCHEMBL264008 | 0.92 | CTRB1 (0.61) | CTRB1CASP1SYKATM | |
| SCHEMBL553906 | 0.92 | CTRB1 (0.61) | CTRB1CASP1SYKATM | |
| SCHEMBL4829896 | 0.85 | CTRB1 (0.68) | CTRB1SYKATMCTSKTACR1 | |
| SCHEMBL7136060 | 0.84 | CTRB1 (0.66) | CTRB1CASP1SYKATMHTT | |
| SCHEMBL14288626 | 0.83 | CTRB1 (0.58) | CTRB1CASP1SYKATMCTSK | |
| SCHEMBL555191 | 0.82 | CTRB1 (0.57) | CTRB1CASP1SYKATMCTSK | |
| SCHEMBL15355257 | 0.82 | CTRB1 (0.57) | CTRB1CASP1SYKATMCTSK | |
| SCHEMBL79250 | 0.82 | CTRB1 (0.57) | CTRB1CASP1SYKATMCTSK | |
| SCHEMBL555192 | 0.82 | CTRB1 (0.57) | CTRB1CASP1SYKATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | CTRB1 4356/4885CASP1 3743/4885SYK 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.